Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
332 stopped studies mapped to Pancreatobiliary Carcinoma and descendants · 93% state a reason
Over the 332 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon,… | Phase 1 | terminated | Mar 19, 2025 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT05685602 | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic… | Phase 1 | suspended | Jan 17, 2023 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine… | Phase 2 | suspended | Sep 22, 2023 | National Cancer Institute (NCI) | Other - evaluation of patients on first stage | Other (stated, no rule matched) |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver… | Phase 1 | suspended | Mar 30, 2023 | University of Southern California | Pending protocol amendment | Other (stated, no rule matched) |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | Phase 2 | terminated | Mar 18, 2022 | National Cancer Institute (NCI) | The study was terminated due to low accrual and insufficient efficacy seen in first few… | Efficacy / futility |
| NCT05737615 | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal,… | Phase 1 | withdrawn | Feb 21, 2023 | Memorial Sloan Kettering Cancer Center | Study tracer is currently unavailable | Other (stated, no rule matched) |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in…(FIGHT-302) | Phase 3 | terminated | Sep 4, 2018 | Incyte Corporation | The study was terminated due to lack of enrollment resulting from a change in the standard of care… | Safety / toxicity |
| NCT04123574 | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | Early Phase 1 | withdrawn | Oct 11, 2019 | BioXcel Therapeutics Inc | No longer relevant to field | Other (stated, no rule matched) |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With… | Phase 1 | terminated | Jul 30, 2024 | Boehringer Ingelheim | not stated | Not stated |
| NCT02200042 | Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable… | Phase 3 | terminated | Jul 25, 2014 | NRG Oncology | not stated | Not stated |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Phase 1 / Phase 2 | terminated | Jul 11, 2022 | TCR2 Therapeutics | No participants were enrolled in Phase 2 as Phase I was terminated early due to the lack of a clear… | Enrollment / accrual |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT06466187 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Phase 1 | terminated | Jun 20, 2024 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT04809766 | Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic… | Phase 1 | terminated | Mar 22, 2021 | Fred Hutchinson Cancer Center | Study terminated due to end of funding. | Funding |
| NCT04251715 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With… | Phase 2 | terminated | Feb 5, 2020 | OHSU Knight Cancer Institute | change in standard-of-care systemic therapy | Other (stated, no rule matched) |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for… | Phase 2 | terminated | Jul 23, 2021 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT02626312 | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma,… | Phase 1 | terminated | Dec 10, 2015 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT04158635 | Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic… | Phase 1 | suspended | Nov 12, 2019 | City of Hope Medical Center | Accrual Goal met | Enrollment / accrual |
| NCT05419479 | Switch Maintenance in Pancreatic | Phase 1 / Phase 2 | suspended | Jun 15, 2022 | James Cleary, MD, PhD | Efficacy concerns. | Efficacy / futility |
| NCT05275075 | Identify microRNAs in Cachexia in Pancreatic Carcinoma(SCC-miRPanCa) | — | terminated | Mar 11, 2022 | University of Oklahoma | Translational scientist left university | Other (stated, no rule matched) |
| NCT04975217 | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer | Early Phase 1 | suspended | Jul 23, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT03825289 | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer(THREAD) | Phase 1 | terminated | Jan 31, 2019 | University of Utah | Lack of Funding | Funding |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2023 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT02072616 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.(CTC-Pancreas) | N/A | terminated | Feb 26, 2014 | University Hospital, Rouen | Analysis not possible at the stage | Other (stated, no rule matched) |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or… | Phase 2 | withdrawn | Jul 22, 2020 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers… | Phase 1 / Phase 2 | terminated | May 13, 2020 | University of Southern California | Study drug no longer available | Other (stated, no rule matched) |
| NCT02872831 | Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle | N/A | withdrawn | Aug 19, 2016 | Thomas Jefferson University | Principal Investigator let the institution prior to study initiation. | Investigator |
| NCT05240040 | Treat Primary and Metastatic Liver Tumors | — | withdrawn | Feb 15, 2022 | Methodist Health System | Resources | Other (stated, no rule matched) |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and…(ALAFOSS-01) | Phase 1 | terminated | Sep 19, 2024 | AstraZeneca | The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01… | Enrollment / accrual |
| NCT05346484 | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With…(MAST) | Phase 1 | terminated | Apr 26, 2022 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT05360745 | Quality of Life With Nutritional Supplementation in Patients With Locally…(FOODPANC) | N/A | withdrawn | May 4, 2022 | Fundacion para la Excelencia y la Calidad de la Oncologia | Few months later the site initiation visit, the principal investigator decided not to continue with… | Investigator |
| NCT05489250 | The PLATON Network(PLATON) | — | terminated | Aug 5, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sponsor Decision | Sponsor / business decision |
| NCT06290856 | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced… | — | terminated | Mar 4, 2024 | Oslo University Hospital | The platform used for detecting ctDNA was not sensitive enough. | Other (stated, no rule matched) |
| NCT06739252 | Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA | Phase 2 | terminated | Dec 18, 2024 | Peking University | Difficulty of participants enrollment | Enrollment / accrual |
| NCT02917759 | Liver and Biliary Tumor Tissue Registry | — | terminated | Sep 28, 2016 | Mayo Clinic | Lack of funding to support enrollment | Enrollment / accrual |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations… | Phase 2 | terminated | Jun 27, 2024 | Lipomedix Pharmaceuticals Inc. | Sponsor decision | Sponsor / business decision |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Phase 1 | terminated | Aug 4, 2023 | Novartis Pharmaceuticals | The decision was not based on any safety concerns | Safety / toxicity |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT06420349 | NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | Phase 1 | terminated | May 20, 2024 | Mayo Clinic | study sponsor phasing out drug supply | Drug supply |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | Phase 2 | terminated | Mar 21, 2022 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT05417386 | FOLFIRINOX + NIS793 in Pancreatic Cancer | Phase 1 | terminated | Jun 14, 2022 | Colin D. Weekes, M.D., PhD | NIS793 is no longer being developed | Other (stated, no rule matched) |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
| NCT02881554 | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or… | N/A | terminated | Aug 29, 2016 | University of Washington | Terminated due to low accrual in Cohort B. (Accrual goal for Cohort A was met.) | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials